BBIO vs ED · rev $221.9M vs P/E 18, rev $15.26B
BridgeBio Pharma Inc (BBIO) versus Consolidated Edison Inc (ED) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
BBIO currently screens at market cap $13.24B. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Not investment advice. Open the BBIO and ED stock pages for the full models.
Not investment advice.